On 9/25/24, Celldex Therapeutics Inc (NASDAQ: CLDX) stock suffered a major decline of -12.1%, closing at $36.02. Moreover, exceptionally high trading volume at 1250% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -12.7% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, CLDX is expected to continue to be a modest Value Builder.
Celldex Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. Celldex Therapeutics has a slightly negative Power Rating of 32 and a very low Appreciation Score of 7, triggering the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment